{"keywords":["BRAF-mutant melanoma","mitochondrial biogenesis","targeted therapies"],"genes":["mitogen activated protein kinase","MAPK","B-Raf proto-oncogene","serine/threonine kinase","BRAF","MAPK"],"publicationTypes":["Journal Article"],"abstract":"The acquisition of resistance to current mitogen activated protein kinase (MAPK) inhibitors in B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutant melanoma is almost inevitable. Our recent findings identify therapy-induced mitochondrial biogenesis (MitoBiogenesis) and aberrant tumor bioenergetics as therapeutic escape mechanisms and offer a rational combinatorial strategy to further improve the efficacy of MAPK inhibitors. ","title":"Mitochondrial biogenesis meets chemoresistance in BRAF-mutant melanoma.","pubmedId":"27652325"}